Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease.
The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up to 24 months in the titration cohort and up to 36 months in the fixed-dose cohorts. The results are consistent with previously reported analyses from this ongoing Phase 1b study and support the design of the ongoing Phase 3 studies of aducanumab for early Alzheimer’s disease.
The Phase 1b is a randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical effects of aducanumab in patients with prodromal or mild Alzheimer’s disease. The study includes fixed dosing at 1, 3, 6 and 10 mg/kg as well as an arm with a titration regimen.
Phase 1b Long-Term Extension
Patients who completed the 54-week, placebo-controlled period of the Phase 1b study had the option to continue in the LTE.
The new analyses include 143 patients who remained in the LTE. The LTE cohorts are small populations:
- Patients (n=18) initially randomized to the aducanumab titration regimen in the 12-month placebo-controlled period and treated up to 24 months
- Patients (n=69) initially randomized to aducanumab 3, 6 or 10 mg/kg and treated up to 36 months
- Patients (n=48) who were randomized to placebo or aducanumab 1 mg/kg in the placebo-controlled period who were switched to aducanumab 3 mg/kg or to a 3-6 mg/kg titration regimen in the LTE and treated up to 24 months
- Patients (n=8) who were randomized to placebo in the placebo-controlled period who were switched to aducanumab 1-3-6-10 mg/kg titration regimen in the LTE and treated up to 12 months
In the Phase 1b LTE, the most commonly reported adverse events were headache, fall and amyloid-related imaging abnormalities (ARIA). Of the 185 patients dosed with aducanumab in the Phase 1b study, 46 patients experienced ARIA-E (edema). There were no new cases of ARIA-E in patients who continued on the same dose of aducanumab. The incidence of ARIA-E in patients switching from placebo to aducanumab was consistent with the incidence reported in the placebo-controlled portion of the Phase 1b study. Six patients experienced more than one episode of ARIA-E. These recurrent events were consistent with other ARIA events reported to date; they were typically asymptomatic, and most patients continued in the study.
In patients treated up to 24 months in the titration cohort, amyloid plaque reduction as measured by positron emission tomography (PET) was consistent with the dose- and time-dependent results observed in the fixed-dose cohorts. Analyses of exploratory clinical endpoints, Clinical Dementia Rating sum of boxes (CDR-SB) and the Mini-Mental State Examination (MMSE), were consistent with the results from the fixed-dose cohorts and suggest a continued benefit on the rate of clinical decline during the second year of treatment.
In patients treated up to 36 months, amyloid plaque as measured by PET continued to decrease in a dose- and time-dependent manner, with amyloid plaque levels in the 10 mg/kg fixed-dose cohort reaching and remaining at a level considered below the quantitative cut-point that discriminates between a positive and negative scan1. At 36 months, analyses of exploratory clinical endpoints CDR-SB and the MMSE suggest a continued benefit on the rate of clinical decline during the third year of treatment.
Biogen plans to share more data from these analyses at an upcoming medical congress.
Read Full Text on the Biogen Web Site
More news
- IREM publication featured in "ZNZ Research News"
- iPSZurich 2022 Symposium
- New dates for starting the BEI program in 2022
- Generali M. et al.: "Heterogeneous Expression of ACE2 and TMPRRS2 in Mesenchymal Stromal Cells" in Journal of Cellular and Molecular Medicine
- IREM at Science Agora
- iPSC Core Facility at IREM
- New publication by Melanie Generali in Journal Genes
- IREM to participate at Scientifica
- Prof Martin Schwab will give this year's "Wings For Life" Lecture
- FDA approval of Aducanumab for the treatment of Alzheimer’s disease
- Ruslan Rust receives 3RCC Grant for "Experimental toolkit to evaluate cell-based therapies in the mouse brain"
- New Minor in BioMedEntrepreneurship
- Dr. Ramona Weber receives a HFSP postdoctoral long-term fellowship
- URPP Kick-off Event 23 March 2021
- New IREM seminar series Innovations in Regenerative Medicine
- New Publication by Ruslan Rust in Journal of Cerebral Blood Flow and Metabolism
- Harnessing cell therapies to fight COVID-19: Basic research, clinical evidence and patient access
- BrainFair 15. - 19.März 2021
- 2nd IREM Scientific Art Photo Competition 2021
- Ruslan Rust receives SNF Spark Grant to develop a brain-shuttle for cell therapies
- Nature - Scientific Reports publication by M. Y. Emmert/ S. Motta and E. Fioretta (first authors)
- Spark grant 2020-2021 awarded to Sarah Motta
- New Publication by Rebecca Weber and Ruslan Rust in Frontiers in Physiology
- Visiting Professor Sandra Loerakker
- New publication in Nature Reviews Cardiology by M.Y. Emmert and colleagues
- Distinct changes in all major components of the neurovascular unit across different neuropathological stages of Alzheimer's disease
- New University Research Priority Programs (URPP) ITINERARE
- Kyoto University and the University of Zurich have officially established a strategic partnership
- Human Cardiac Organoids for Modeling Genetic Cardiomyopathy
- New Minor in BioMed Entrepreneurship at IREM
- Therapeutic antibodies targeting CNS : Comparative Study by Correa et al. of intrathecal, intravenous, and subcutaneous anti-Nogo A antibody treatment after stroke in rats
- Wrona et al.: CRISPR-Directed Therapeutic Correction at the NCF1 Locus Is Challenged by Frequent Incidence of Chromosomal Deletions
- Two of our IREM scientists – Debora Kehl and Ruslan Rust – have been selected to participate on the 70th Nobel Laureate Meeting
- Ruslan Rust et al. in Frontiers in Neuroscience: A Practical Guide to the Automated Analysis of Vascular Growth, Maturation and Injury in the Brain
- IREM Organization Update
- Ruslan Rust et al. in JCBFM: "Insights Into the Dual Role of Angiogenesis Following Stroke"
- New publication of Fioretta et al. in JACC: Basic to Translational Science.
- Prof. Dr. Janine Reichenbach new associate professor for Somatic Gene Therapy
- IREM Professor Janine Reichenbach is member of the new HMZ flagship project Immuno-TargET.
- IREM Professor Max Emmert receives Techno-College Innovation Award
- Fixing Hearts, Saving Lives
- Rust et al: Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke.
- Unconventional research and novel scientific approaches: Two Spark grants awarded to IREM researchers
- First iPSC lecture will take place at the University of Zurich
- New analysis of study results showed clinical benefit of Aducanumab
- UZH IncubatorLab: Mit Era-107 den Appetit sanft bändigen
- ISACB+ISVTE conference abstracts published
- ERC Starting Grant awarded to Prof. Maximilian Emmert
- S. Motta et al.: Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements; new publication in npj Regenerative Medicine - Nature.
- Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells
- Rust et al: Review on Therapeutic Angiogenesis in «Trends in Neurosciences»
- Sherida de Leeuw and Christian Tackenberg, “Alzheimer’s in a dish – Induced pluripotent stem cell-based disease modeling”, published in Translational Neurodegeneration
- Frank Baaijens, Rektor TU Eindhoven and Visiting Professor IREM: Die TU Eindhoven stellt nur noch Frauen ein.
- Rust et al: New Therapy Promotes Vascular Repair Following Stroke
- Debora Kehl et al. in "Nature Regenerative Medicine"
- Janine Reichenbach in UZH magazine
- Visiting Professor Frank Baaijens
- Annual meeting 2019 of medAlumni UZH took place at IREM
- RESTORE (with IREM participation) is one of the winners of a pan-European competition addressing grand scientific and technological challenges that could change our future.
- Review about iPSC microglia in “Stem Cells”
- Article in «Tages-Anzeiger» from 25 Jan 2019 portrays the Wyss Zurich Lab at Moussonstrasse and their Co-Director Simon P. Hoerstrup.
- Cover Story and Cover Picture on "Science Translational Medicine"
- Neuroscience Center Zurich Membership for Dr. Christian Tackenberg
- Certificate of Excellence for Dr. Katrin Rauen
- Sex differences in Alzheimer disease ‒ the gateway to precision medicine: Article in "Nature Reviews Neurology"
- RESTORE successfully passed the first round of the FET Flagship competition and is preparing for the next phase
- Computer-designed heart valves implanted into sheep for the first time
- UZH Start-Up Funding for Young Innovators
- Vom Computer massgeschneiderte regenerative Herzklappen
- IREM Director Prof. Simon Hoerstrup meets Dr. Craig Venter (J.Craig Venter Institute and Human Longevity Inc., La Jolla, California
- Award-Winning Medical Research
- Standort Zürich hat Trümpfe für Biotechnologie in der Hand
- IREM research project awarded with UZH Forschungskredit
- IREM in Boston
- Engineering heart valves for the many
- Stammzellenforschung: Mitwachsende Prothesen für Babyherzen
- Article "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease" among top 100 most-discussed journal articles of 2016 Foreign Policy magazine recognizes Prof. R. Nitsch as one of the "Top 100 Global Thinkers 2016"
- Antibody Aducanumab Reduces Brain Amyloid Plaques in Alzheimer's Patients
- The Aino University in Osaka, Japan, conferred on the IREM Director Prof. Roger M. Nitsch the title of distinction "Overseas Visiting Professor of Health Science". In honor of outstanding performance and dedication in the field of education and research of health science.
- Royal Society of Medicine London, UK: Living engineered matrices to regenerate the heart (LifeMatrix); Interview with Professor Sir Magdi Yacoub and Professor Simon P. Hoerstrup / Royal Society of Medicine London, GB: Lebende Matrices zur Wiederherstellung des Herzens (LifeMatrix); Interview mit Professor Sir Magdi Yacoub und Professor Simon P. Hoerstrup
- 3D-printer in medicine - bio-ink for organs / 3D-Drucker in der Medizin - Bio-Tinte für neue Organe
- Zurich meets London: From Russell Square to Oxford Circus / Zürich trifft London: Vom Russel Square zum Oxford Circus
- At the "Dies academicus 2016 " at the University of Zurich Prof. Dr. Maximilian Emmert was awarded by the science prize of Walter and Gertrud Siegenthaler Foundation / Am "Dies academicus 2016" der Universität Zürich wurde der Wissenschaftspreis der Walter und Gertrud Siegenthaler Stiftung an Prof. Dr. Maximilian Emmert vergeben
- Start of Clinical Study with Aducanumab / Start einer klinischen Studie zu Aducanumab
- Roger Nitsch honored at Alzheimer's translation and therapeutic panel and luncheon by the American Federation for Aging Research (AFAR)
- ETH and University of Zurich found Wyss Translational Center Zurich / ETH und Universität Zürich gründen Wyss Translational Center Zurich
- Swiss researchers transplanted first artificial skin / Schweizer Forscher verpflanzen erstmals Kunsthaut
- Growing heart valves - spare valves for the heart with regeneration potential / Mitwachsende Herzklappen - Regenerationsfähige Ersatzventile für das Herz
- The University of Zurich and the Wyss Institute at Harvard University start partnership / Die Universität Zürich und das Wyss Institute der Harvard University gehen Partnerschaft ein
- From our own breeding / Aus eigener Zucht
- Researchers are working on heart valves for babies / Forscher arbeiten an Herzklappen für Babys
- Cell- and Tissue Biobank (CTBB) membership "Gemeinschaft Deutscher Kryobanken e.V."
- Tissue for heart repair / Gewebe für Herzreparatur
- It will be possible to recreate organs in the laboratory / Es wird möglich sein, Organe im Labor nachzubauen
- Artificial skin for burn victims / Künstliche Haut für Brandopfer
- The science in the footsteps of Prometheus / Die Wissenschaft auf den Spuren von Prometheus
- Researchers from Zurich grow skin for children with burns / Zürcher Forscher züchten Haut für Kinder mit Verbrennungen
- Vein replacement from their own stem cells / Venen-Ersatz aus den eigenen Stammzellen
- With tissue engineering against tissue and organ damage / Mit Tissue Engineering gegen Gewebe- und Organschäden
- Organs out of the bioreactor / Organe aus dem Bioreaktor
- 9.9 million euros for the research project "Life VALVE" at the University of Zurich and the University Hospital Zurich / 9.9 Millionen Euro für das Forschungsprojekt „LifeVALVE” an der Universität und am UniversitätsSpital Zürich